Key Highlights
- $120M Series B funding raised quietly in 2024, reinforcing Prenuvo’s leadership in proactive health.
- 1.4M+ personalized health insights identified across its growing member base.
- FDA clearance granted for the AI-powered Prenuvo Body Composition report.
- Expansion into 15 new clinics, including Europe and Australia, to advance preventative healthcare.
- New product launches include whole-body composition analysis, brain health scans, and biomarker assessments.
Source: Business Wire
Notable Quotes
- “Prenuvo is leading a movement to make proactive healthcare accessible and transformative for everyone.” – Andrew Lacy, CEO at Prenuvo
- “Last year demonstrated an unmistakable shift in consumer behavior towards proactive health management.” – Sundeep Peechu, Managing Partner at Felicis
- “Longevity is the new luxury and Prenuvo is democratizing access so that more can benefit from this.” – Brian O’Malley, Partner at Forerunner Ventures
Why This Matters
With only 2.5% of U.S. healthcare spending focused on prevention, Prenuvo is reshaping the landscape by providing AI-powered whole-body MRI scans that empower individuals to detect diseases before symptoms emerge. By securing $120M in funding and expanding internationally, Prenuvo is at the forefront of proactive healthcare, giving people the knowledge and tools to live longer, healthier lives.
